Description de l'entreprise
Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics—ONPATTRO® (patisiran) in 2018, GIVLAARI® (givosiran) in 2019, OXLUMO® (lumasiran) in 2020, and AMVUTTRA® (vutrisiran) in 2022. We are advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Conseil d'administration & Conseil de surveillance
| PDG |
| Yvonne Greenstreet |
| Conseil d'administration |
| Jeff Poulton, Akshay Vaishnaw, Pushkal Garg, Kelley Boucher, Tim Maines, Tolga Tanguler, Indrani Franchini, Piyush Sharma, Evan Lippman, Kevin Fitzgerald |
| Conseil de surveillance |
| Amy W. Schulman, Dennis A. Ausiello, Carolyn Bertozzi, Michael W. Bonney, Olivier Brandicourt, Marsha H. Fanucci, Yvonne Greenstreet, Margaret A. Hamburg, Peter N. Kellogg, David E.I. Pyott, Colleen F. Reitan, Phillip A. Sharp, Elliott Sigal |
Données de l'entreprise
| Nom: |
Alnylam Pharmaceuticals, Inc |
| Adresse: |
675 West Kendall St,Cambridge, MA 02142 |
| Téléphone: |
+1 617-551-8200 |
| Fax: |
+1 617-551-8101 |
| Courriel: |
INFO@ALNYLAM.COM
|
| Internet: |
https://www.alnylam.com/ |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
- |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
- |
| IPO date: |
01/05/2004 |
